Citace podle APA

Herting, F., Friess, T., Bader, S., Muth, G., Hölzlwimmer, G., Rieder, N., . . . Klein, C. (2014). Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma. Informa Healthcare.

Styl Chicago

Herting, Frank, Thomas Friess, Sabine Bader, Gunter Muth, Gabriele Hölzlwimmer, Natascha Rieder, Pablo Umana, a Christian Klein. Enhanced Anti-tumor Activity of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) in Combination With Chemotherapy in Xenograft Models of Human Lymphoma. Informa Healthcare, 2014.

Citace podle MLA

Herting, Frank, et al. Enhanced Anti-tumor Activity of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) in Combination With Chemotherapy in Xenograft Models of Human Lymphoma. Informa Healthcare, 2014.

Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..